Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models

[1]  M. Socinski,et al.  PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer , 2018, Molecular Diagnosis & Therapy.

[2]  J. Banchereau,et al.  Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Yiling Lu,et al.  A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. , 2017, Cell reports.

[4]  B. Levy,et al.  Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer. , 2017, Annals of translational medicine.

[5]  L. Rubinstein,et al.  The Challenge for Development of Valuable Immuno-oncology Biomarkers , 2017, Clinical Cancer Research.

[6]  L. Emens.  Breast Cancer Immunotherapy: Facts and Hopes , 2017, Clinical Cancer Research.

[7]  M. Socinski,et al.  First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[8]  Donald A. Berry,et al.  Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. , 2017 .

[9]  Sung-Bae Kim,et al.  Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. , 2017 .

[10]  S. Fox,et al.  Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. , 2017, Pathology.

[11]  G. Botti,et al.  Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients , 2017, International journal of molecular sciences.

[12]  Hans Clevers,et al.  Interrogating open issues in cancer precision medicine with patient-derived xenografts , 2017, Nature Reviews Cancer.

[13]  Masafumi Nakamura,et al.  The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer , 2017, Oncotarget.

[14]  A. Jimeno,et al.  Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. , 2016, Cancer research.

[15]  C. Cohen,et al.  Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. , 2016, American journal of clinical pathology.

[16]  Lajos Pusztai,et al.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Janice S. Sung,et al.  A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling , 2016, Clinical Cancer Research.

[18]  J. Hipp,et al.  Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? , 2016, Drugs.

[19]  J. Banchereau,et al.  Patient-derived tumor xenografts in humanized NSG-SGM3 mice: A new immuno-oncology platform. , 2016 .

[20]  Donna Neuberg,et al.  The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. , 2016, Cancer cell.

[21]  F. Marincola,et al.  Checkpoint Inhibitors and Their Application in Breast Cancer , 2016, Breast Care.

[22]  Carsten Denkert,et al.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.

[23]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[24]  A. Ribas.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack. , 2015, Cancer discovery.

[25]  Xue Han,et al.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.

[26]  C. Bult,et al.  Abstract LB-050: Patient-derived tumor xenografts in humanized NSG mice: a model to study immune responses in cancer therapy , 2015 .

[27]  L. Molinero,et al.  Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) , 2015 .

[28]  E. Compérat,et al.  Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors? , 2015, Current Urology Reports.

[29]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[30]  A. Jimeno,et al.  XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer , 2015, Oncogene.

[31]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[32]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[33]  Hong Zhao,et al.  Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer , 2015, Breast Cancer Research.

[34]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[36]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[37]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[38]  Stephen T C Wong,et al.  Chloroquine Eliminates Cancer Stem Cells Through Deregulation of Jak2 and DNMT1 , 2014, Stem cells.

[39]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Marcus Schmidt,et al.  Co-transplantation of human hematopoietic stem cells and human breast cancer cells in NSG mice , 2014, mAbs.

[41]  P. Sharma,et al.  PD-L1 Expression in Triple-Negative Breast Cancer , 2014, Cancer Immunology Research.

[42]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[43]  Chad A Shaw,et al.  A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. , 2013, Cancer research.

[44]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[45]  A. Hauschild,et al.  Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Jenny C. Chang,et al.  Patient-derived breast tumor xenografts facilitating personalized cancer therapy , 2013, Breast Cancer Research.

[47]  Ian Krop,et al.  Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors , 2013, Clinical Cancer Research.

[48]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[49]  A. Bardelli,et al.  Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas , 2012, Clinical Cancer Research.

[50]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[51]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[52]  F. Mohr,et al.  Ten-year follow up after prospectively randomized evaluation of stentless versus conventional xenograft aortic valve replacement. , 2011, Journal of Heart Valve Disease.

[53]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[54]  M. Maio,et al.  Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. , 2010, Seminars in oncology.

[55]  Mark T. W. Ebbert,et al.  A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[56]  P. LoRusso,et al.  Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells , 2010, Clinical Cancer Research.

[57]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[58]  D. Greiner,et al.  Creation of “Humanized” Mice to Study Human Immunity , 2008, Current protocols in immunology.

[59]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[60]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[61]  A. Vincent-Salomon,et al.  A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays , 2007, Clinical Cancer Research.

[62]  T. Okazaki,et al.  PD-1 and PD-1 ligands: from discovery to clinical application. , 2007, International immunology.

[63]  Guangwu Xu,et al.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know , 2006, Cell Research.

[64]  A. Maier,et al.  Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. , 2004, European journal of cancer.

[65]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[67]  B. Evers,et al.  Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[69]  A. Cesano,et al.  Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. , 1998, The American journal of pathology.

[70]  P. Linsley,et al.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.

[71]  H. Yaziji,et al.  PD-L1 Assessment for Targeted Therapy Testing in Cancer: Urgent Need For Realistic Economic and Practice Expectations. , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[72]  D. Greiner,et al.  Generation of Immunodeficient Mice Bearing Human Immune Systems by the Engraftment of Hematopoietic Stem Cells. , 2016, Methods in molecular biology.

[73]  Christopher B Wilson,et al.  Regulation of interferon-gamma during innate and adaptive immune responses. , 2007, Advances in immunology.